SCHEMBL32665010

SCHEMBL32665010

Cc1cccc(-c2ncc3ccc(-c4ccc(C(=O)O)c(Cl)c4)cn23)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.50
AKR1C1 Q04828 1/20 0.50
DHODH Q02127 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.41
MCL1 Q07820 1/20 0.40
GRIN2B Q13224 4/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
RPA1 P27694 1/20 0.38
XDH P47989 3/20 0.38
SLC22A12 Q96S37 2/20 0.38
KMO O15229 1/20 0.38
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32665006 0.89 KDM4E (0.42) AKR1C2AKR1C1DHODHKDM4EMAPT
SCHEMBL32664975 0.85 ALDH1A1 (0.52) DHODHKDM4EMAPTALDH1A1HPGD
SCHEMBL32664893 0.85 CAMKK2 (0.43) AKR1C2AKR1C1DHODHKDM4EMAPT
SCHEMBL32664937 0.82 RXRA (0.47) DHODHKDM4EMAPTALDH1A1HPGD
SCHEMBL6508314 0.82 AKR1C2 (0.70) AKR1C2AKR1C1DHODHSMN1; SMN2MCL1
SCHEMBL32665023 0.81 KMO (0.45) KDM4EMAPTALDH1A1HPGDRAB9A
SCHEMBL32665317 0.80 KDR (0.43) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL32665218 0.80 ALDH1A1 (0.49) DHODHKDM4EMAPTALDH1A1HPGD
SCHEMBL26459335 0.78 PRMT5 (0.44) ALDH1A1HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL32665100 0.76 RAB9A (0.49) KDM4EMAPTALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIV MINNESOTA (US) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS NR5A1, CYP17A1, CNR1 AKR1C2 215/4885AKR1C1 253/4885DHODH 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.